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As the ongoing outbreak in the Democratic Republic of Congo illustrates, Ebola virus
disease continues to pose a significant risk to humankind and this necessitates the
continued development of therapeutic options. One option that warrants evaluation
is that of defective genomes; these can potentially parasitize resources from the
wild-type virus and may even be packaged for repeated co-infection cycles. Deletion
and copy-back defective genomes have been identified and reported in the literature. As
a crude, mixed preparation these were found to have limiting effects on cytopathology.
Here we have used synthetic virology to clone and manufacture two deletion defective
genomes. These genomes were tested with Ebola virus using in vitro cell culture and
shown to inhibit viral replication; however, and against expectations, the defective
genomes were not released in biologically significant numbers. We propose that EBOV
might have yet unknown mechanisms to prevent parasitisation by defective interfering
particles beyond the known mechanism that prevents sequential infection of the same
cell. Understanding this mechanism would be necessary in any development of a
defective interfering particle-based therapy.
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INTRODUCTION
Like all of the filoviridae, the Ebola virus (EBOV) genome is composed of a negative sense single
stranded RNA, which is present in the cell as a ribonucleoprotein complex (RNP). During virus
assembly this RNP becomes enveloped in a host-cell phospholipid membrane, by incorporating
various viral membrane proteins, including the glycoprotein (Martin et al., 2018). The virus is
believed to survive long term in an environmental niche that is likely to involve species of African
bats (Singh et al., 2017). Occasionally the virus jumps the species barrier and causes outbreaks
of Ebola virus disease (EVD) in humans, which is severe with characteristic fever, viraemia and
occasionally hemorrhage (Brown et al., 2017), and a case fatality rate as high as 80% in some
outbreaks (Nyakarahuka et al., 2016). The virus is transmissible between people via contact with
body fluids and is therefore capable of causing epidemics of varying sizes (Brown et al., 2017). At
the time of writing this article, the most serious epidemic to date occurred in West Africa in 2014;
however there is currently an uncontrolled outbreak in the Democratic Republic of Congo (World
Health Organization, 2018) and spreading into Uganda.
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Viral defective interfering particles (DIPs) were first described
in the 1950’s in influenza virus (Gard et al., 1952). DIPs are
viral particles capable of translocating between cells but, they
contain defective genomes. The defective genomes are unable to
reproduce themselves or manufacture all the proteins required
for viral assembly. DIPs can, however, replicate when co-infected
with wild-type virus, potentially to the detriment of the wild-type
virus by sequestering cellular resources and viral proteins. In the
mononegavirales (a family of viruses where genomes are encoded
by a single negative strand of RNA and of which EBOV is a
member), defective genomes spontaneously arise due to incorrect
amplification of the genome. The first DIPs in mononegavirales
were found in vesicular stomatitis virus Indiana strain (Huang
and Baltimore, 1970). There are thought to be two main types
of defective genome. Deletion defective genomes arise where a
fusion event occurs between the 3’ and 5’ ends of the genome,
possibly where a loop has formed. The result is a genome with
(normally) large regions of coding sequence being deleted but
with the 3’ and 5’ ends intact (Resende Rde et al., 1992). Copy-
back defective genomes are believed to form when the RNA
dependent RNA polymerase (RdRP) copies back onto the strand
under construction. The result is a genome with the same origin
of replication at both ends; one in sense and one in anti-sense.
These are usually the wild-type’s 5’ end (in antisense form)
because genomic replication is heavily biased for antisense to
sense replication (Schubert and Lazzarini, 1981).
With regards to EBOV, DIPs were first described by Calain
et al. (1999). In their study, Calain et al. used a serial passage at
high multiplicity of infection (MOI) to enhance the probability
of defective genome formation. They mapped several of these
and found that, when they were co-infected with the low
passage virus, cytopathology was tempered. It is difficult to
say what role DIPs might play in actual human infection;
however, Calain et al. later suggested that it was possible that
defective genomes played a role in latent infections possibly
observed in cases of EVD where there is recrudescence several
months after patients are convalescent and EBOV negative
in their bloods (Calain et al., 2016). It is unclear why, since
DIPs are readily generated in the laboratory, and they temper
viral pathology, we are unable to find reports of epidemics
and disease in individuals spontaneously resolving because of
DIPs. One reason might be that EBOV is known to have the
ability to prevent further infection of the cell that it infects (i.e.,
to prevent super-infection/co-infection). This phenomenon of
infection blockade is driven by the 1-peptide (Radoshitzky et al.,
2011). In the studies by Calain et al. (1999), DIPs were used at
high MOI and simultaneously to the wild-type virus infection.
Therefore, coinfection in these studies was significantly more
probable. Conversely in epidemics, and in the host, EBOV is a
budding virus (Martin et al., 2018) and this means exposure of
neighboring cells will occur across a greater time period than for a
bursting virus. This prevention of super-infection/co-infection is
therefore likely to provide a natural defense against parasitisation
by DIPs. The existence of a system of infection blockade does
not however preclude the possibility that DIPs might be useful
as therapies provided one of the following considerations are
taken on board: (1) deliver defective genomes prior to EBOV
and in a manner that does not preclude super infection (i.e.,
absence of 1-peptide), (2) use a route of cellular entry that is
independent of EBOV uptake, or (3) be available systemically at
high titer.
Here we have explored the impact that defective genomes of
EBOV might offer by considering their therapeutic potential, in
in vitro infection studies as synthetic constructs. It is obviously
not conceivable to use the high passage mixed population of
virus and DIP observed by Calain et al. (1999) because of safety
issues associated with an uncharacterised population containing
real virus. For this reason nucleic acid synthesis and molecular
biology were used to recreate and evaluate the therapeutic
potential of two of the defective genomes that Calain et al.
(1999) characterized.
MATERIALS AND METHODS
Construction and Quantification of
Defective Genomes
For the first deletion defective genome (hereafter referred to as
DG-d1) described by Calain et al. (1999) a T7 promoter sequence
was cloned along with the last 618 nt of the 5′ end of the EBOV-
Makona genome and the first 373 nt of the 3′ end of the EBOV-
Makona genome including the translational start codon of the
NP gene (antisense strand from 5′ to 3′), a hepatitis delta virus
ribozyme sequence and the T7 terminator sequence. For one of
the other deletion defective genomes described by Calain et al.
(1999) (hereafter referred to as DG-d2) a T7 promoter sequence
was inserted along with the last 672 nt of the 5′ end of the
EBOV-Makona genome and the first 155 nt of the 3′ end of the
EBOV-Makona genome (Genebank Accession KJ660347.2). All
plasmids preparations and synthesis were done by GeneArtTM
(ThermoFisher Scientific, UK). The DIs were synthesized and
then inserted into a cloning plasmid (pMK-RQ), after that the
insert was cut and put into the appropriate expression plasmid
(pUC 57_A338), which is the same backbone plasmids used for
the EBOV min-genome system. This genome template was used
so that a mini-genome system might be used as part of an initial
screen (Mühlberger, 2007). The output of mini-genome-based
assay broadly correlated with that of the high containment assay
(data not shown).
In order to test deletion defective genomes in cell lines that
do not express the T7 polymerase, for example Vero C1008
cells, RNA from the DIP plasmids was made in vitro. The
MEGAscript R© T7 transcription kit was used (Thermo Fisher,
AM1333) following the instructions of the manufacturer.
The control RNA used was the pTRI-Xef control template,
from the MEGAscript R© T7 transcription kit, which is a
linearized TRIPLEscript plasmid containing the 1.85 kb Xenopus
elongation factor 1α gene under the transcriptional control of T7
promoter (pTRI-Xef 1). The size of the transcript after the in vitro
transcription is 1.87 kb.
The DG-d1 genomes were quantified using a bespoke PCR
methodology. The reverse transcription (RT) step was done
using a SuperScriptTM IV First-Strand Synthesis System (Thermo
Fisher – 18091050) and gene-specific primers (forward =
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TTGAACCTGAAAACGAAAGGAGTCC, reverse = AGCC
CAGACCTATCGTTAAAGC) following the manufacturer’s
instructions (Thermo Fisher; UK). A mixture of 1 µg of
RNA from the samples was mixed with 20µM of DG-d1 or
primers, 2 µL of 10mM dNTP mix and completed with Diethyl
pyrocarbonate -treated water up to 13 µL. The mixture was then
incubated at 65◦C for 5min, then cooled on ice for 1min and
8 µl of the cDNA synthesis mix was added (4 µL of 5X Super
Script IV buffer, 1 µl of DTT (100mM), 1 µl of Ribonuclease
Inhibitor, and 1 µL of SuperScript TM IV Reverse Transcriptase).
The mixture was incubated at 55◦C for 10min and finally 1 µL
of RNaseH was added to the mixture and incubated at 37◦C for
20min. To do the Real-time PCR, an iTaqTM Universal SYBR R©
Green Supermix (BIO-RAD, 1725120) was used following the
instructions of the manufacturer. Several controls were used
for this, including RNA from DG-d1 (for the RT step) and
a DG-d2 plasmid with Pol1 Promoter (PCR control). The
conditions for the Real-time PCR were 1 step at 95◦C for 2min
and 30 steps at 95◦C for 30 s, then 55◦C for 30 s and 72◦C
for 30 s.
Cells
Vero C1008 cells (ECACC Cat. No.85020206) were obtained
from Culture Collection, Public Health England, UK. Vero
C1008 cells were maintained in Dulbecco’s minimum essential
media supplemented with 10% (v/v) fetal calf serum, 1% (v/v)
L-glutamine and 1% (v/v) penicillin/streptomycin (Sigma). For
experimental purposes, the fetal calf serum concentration was
reduced to 2% (v/v).
Ebola Virus Growth and Manipulation
Ebola virus H. sapiens-tc/COD/1976/Yambuku-Ecran, hereafter
referred to as EBOV-Ecran was used in all studies. This virus,
previously known as EBOV “E718” (Kuhn et al., 2014) was
supplied by Public Health England. Passage 5 material was used
to infect Vero C1008 cells. Virus was harvested on day 5 post-
inoculation and titrated to produce a working stock at 1 × 107
TCID50/mL. This strain was selected because it would be able
to directly transition into mouse studies should the strategy be
found to be sufficiently effective to warrant further study. The
disparity between viral strains used to generate the defective
genomes was considered bioinformatically and, comparing
the EBOV reference sequence from 1976 (NC_002549.1)
with KJ660347.2, there was no nucleotide difference in the
leader sequence of this virus when you compared with the
EBOV Mayinga reference sequence from NCBI: NC_002549.1.
However, there were few nucleotide differences in the trailer
region when compare both viruses.
EBOV-Ecran was titrated in 96-well plates using the endpoint
fifty percent tissue culture infectious dose (TCID50) assay
(Smither et al., 2013). Briefly, virus was 10-fold serially diluted
in 96-well plates of Vero C1008 cells. After 1 week of incubation
at 37◦C/5% CO2, all wells were observed under the microscope
and scored for presence or absence of cytopathic effects. The
50% end-point was then calculated using the method of Reed
and Muench (1938). RNA extractions were performed using the
QiAMP Viral RNA Mini Kit (Qiagen, UK). Two 50 µL elutions
were performed for each sample to increase the volume available
for RT-PCR.
In order to test the effect of the defective genomes in cells
infected with EBOV-Ecran the genetic material of EBOV-Ecran
was quantified using the RealStar R© Filovirus Screen RT-PCR
Kit (Altona diagnostics, Country) following the instructions
of the manufacturer. Relevant positive controls were included.
We have performed this assay many times against a standard
curve of plasmid containing the L gene from EBOV-Ecran
(the plasmid was taken from an established mini-replicon
assay Mühlberger, 2007 and the copy number was estimated
from the concentration, estimated using a nanodrop and the
online tool https://cels.uri.edu/gsc/cndna.html). We found that
the equation GE (genome equivalents) = 258.37-1.17Ct can
be used to estimate the number of genomes from the Ct
values (Supplemental Material 1, Supplemental Figure 1). In
this context “GE” might consist of incomplete negative sense
RNA molecules encoding this sequence of the L gene. However,
we do not believe that these will be common (< 5%) based
upon observations made with next generation sequencing (paper
in preparation).
We found that the qRT-PCR for DG-d1 could be similarly
be used to provide estimates of copy numbers where the
equations is GE (genome equivalents) = 249.02 - 0.87×Cq
(Supplemental Material 1, Supplemental Figure 2). The
numbers of copies in the standard curve were estimated using
the nanodrop and online tool as above. Both qRT-PCR assays
were performed using the BIORAD CFX Connect – Real
Time System.
Efficacy Assays
Twenty-four well plates were seeded with Vero C1008 cells at
2 × 105 cells/mL (1 mL/well). EBOV-Ecran was added to the
cells at an MOI= 5 and after 2 h incubation at 37◦C/5% CO2 the
supernatant was removed. Transfection was performed following
the manufacturer’s instructions with 2.5 µL Lipofectamine
2000 R© (Invitrogen) and 1 µg RNA (defective genome or control
RNA, at 500 ng/µL, produced in this study) in a final volume of
500µL Optimem Reduced Serummedia (Fisher Scientific). After
addition of the transfection reagents, cells were incubated for 4 h
at 37◦C/5% CO2 and then washed twice with tissue culture media
and 1mL of media was added to each well. Supernatant samples
were collected and used for viral enumeration by TCID50 assay
and RNA extractions. Samples were collected 6 h and 48 h after
EBOV-Ecran infection.
Statistical Analysis
Graphs were prepared using the software Graphpad PRISM
V7.0. Statistical analyses were performed using IBM SPSS V21.0.
For the correlation analysis, all data were transformed to the
logarithm of 10 in order to better fit a Gaussian distribution.
Both Pearson’s and partial correlations were performed. To test
the effect of transfection with defective genomes the ratio of virus
released between control and test was found and subjected to 1
sample T-test.
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FIGURE 1 | Genetic maps of the defective genome constructs from Calain
et al. (1999). The Light orange region correspond to regions of the backbone
plasmid (pUC 57_A338); the gray regions correspond to the virus regions that
were used from the EBOV viral sequence (KJ660347.2). The colors are for
guidance only.
RESULTS
Design of Defective Genomes
In order to investigate the effect of defective genomes on
viral biology two candidates were chosen from a study that
identified and characterized DIs in cell culture. Data was
used from previously published work (Calain et al., 1999) to
synthetically recreate two defective genome clones DG-d1 and
DG-d2 (Figure 1). The cDNA of these molecules was cloned
into a plasmid backbone for amplification. The DI sequence was
flanked by a T7 promoter for synthesis of RNA and a HDV
ribozyme and T7 terminator to ensure near authentic 3′ and
5′ termini.
Defective Genomes Reduce Viral
Replication
In order to evaluate the potential for defective genomes to
reduce viral progeny, Vero C1008 cells were infected with EBOV-
Ecran. After infection, the cells were washed and transfected
with the defective genome. Some wells of cells were harvested
at this stage (6 h post exposure to virus and 4 h post exposure
to defective genome RNA) to assess how much of virus and
RNA had entered the cells. Later, after 48 h, more samples
were taken from the supernatant to evaluate how much virus
had been released. Under initial conditions, no evidence was
found for differences in EBOV-Ecran wild-type viral uptake
between cells exposed to the different RNA molecule (none,
control or defective genome; when measured by qRT-PCR).
The qRT-PCR assay used here targets a sequence in the L
gene that is not encoded by the defective genomes. This makes
cross reactivity highly unlikely. Moreover, this assay does not
give signal in control groups where cells were transfected with
defective genomes and but not infected by virus. A strong
correlation was observed between the uptake (measured by qRT-
PCR) in the non-transfected and RNA transfected controls (P
= 0.007) indicating that variability existed extra-experimentally
(Supplemental Material 2, Supplemental Figure 3). Given that
a small range of viral uptake (measured by qRT-PCR) had
occurred, we considered the question of whether the uptake
might influence the viral output (Supplemental Figure 3). A
partial correlation analysis was performed comparing uptake
data to the output data (48 h later), where the analysis controlled
for the treatment group effects. This analysis did not suggest that
any variation in uptake influenced viral output (R = 0.388, P
= 0.067).
After 48 h of growth, viral progeny was estimated in the
supernatant (Figure 2A). This time point was selected because
viral release occurred at this time with minimal viral particle
degradation in the supernatant (data not shown). Across each
experiment, the addition of either DG-d1 or DG-d2 defective
genomes had reduced the numbers of viral progeny by ∼50%
(estimated by qRT-PCR) when compared to cells infected with
just EBOV or EBOV and a non-specific control RNA). Each
deletion defective genome was compared to controls 4 times for
statistical rigor and this effect on release of EBOV RNA from cells
was robust (P = 0.001, for both DG-d1 and DG-d2). The assay
was of sufficient power to identify that the transfection of control
RNA had a small negative effect on viral release (P = 0.024).
Viral release was also measured by TCID50 assay. The TCID50
data generated was generally confirmatory of the qRT-PCR
data; however, we found the TCID50 assay had inherently
more variability (Figure 2B). When compared to the transfected
control we found both DG-d1 and DG-d2 reduced the TCID50
titres (P = 0.118, P = 0.054, respectively). The TCID50 broadly
data supports the qRT-PCR data; however not to the same level
of confidence.
Defective Genomes Are Not Released
One of the potential strengths of using DIPs as a therapeutic is
that they might parasitize wild type virus to propagate. In this
way their pharmacokinetics may self-regulate (or self-propagate)
to the requirement (the level of infection occurring). This is less
feasible when considering EBOV due to the remarkable speed
by which EBOV blocks “super-infection;” however, this is very
much still a point of interest. We hypothesized that there are two
mechanisms by which these defective genomes might interfere
with viral replication. Firstly, the defective genomes might be
replicated, sequestering and using resources for the replication
of wild-type genomes. Secondly, the defective genomes might
parasitize viral proteins. Additionally, it is possible that both of
these assertions are correct. It is important to evaluate which (if
either) of these are likely to be true. In order to assess the potential
for the deletion defective genomes to propagate alongside the
wild-type virus, a qRT-PCR method was developed where one
primer recognizes only the unique fusion sequence of defective
genome DG-d1. Cross-reactivity of this assay is highly unlikely.
This fusion sequence does not exist in wild-type virus. Moreover,
this assay does not give signal in control groups where cells were
infected with wild-type virus but not transfected with defective
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FIGURE 2 | The effect of defective genomes on viral release. 2× 105 Vero c1008 cells were infected with 1× 106 TCID50 infectious units of EBOV strain Ecran
(∼ 1× 1012 genomes) for 2 h then washed. The cells were then transfected with 1 µg of control RNA (red dots) or DG-d1 RNA (blue dots) RNA or DG-d2 RNA (purple
dots) for 4 h. Un-treated Ebola virus only infection was used for comparison. The cells were then incubated and cell culture supernatants at 48 h post infection were
taken and analyzed. The virus was enumerated using qRT-PCR (A) and TCID50 assay (B). Data shown are normalized to the EBOV-Ecran only control for each
experiment. One sample T-tests were performed to indicate the likelihood that the difference would have occurred through random chance. The P-values are given for
the 95% level. Each data point is an independent experiment and the geometric mean of 3 replicates generated from independent wells within the same experiment.
FIGURE 3 | The release of defective genomes. 2× 105 Vero c1008 cells were infected with 1× 106 TCID50 infectious units of EBOV strain Ecran (∼ 1× 10
12
genomes) for 2 h then washed. The cells were then transfected with 1 µg of DG-d1 RNA for 4 h. The cells were then incubated. Samples of the cells at time 0 and
supernatant at 48 h post infection were taken. The viral genomes (defective and wild-type) were enumerated using qRT-PCR. The graph shows the count of each viral
type (wild-type and DG-d1) within the cells at the onset of the experiment and the counts of viral type in the extracellular space after 48 h. Each data point is the
geometric mean (± 95% confidence intervals) of 3 independent experiments, where each experiment is the geometric mean of 3 replicates generated from
independent wells within the same experiment. Where EBOV Ecran was measured, black lines link the data points and the gray circles indicate non-transfected
control infected cells, the red circles indicate infected cells transfected with control RNA and the blue circles indicate the infected cells transfected with DG-d1. Where
the DG-d1 was measured, the green lines link the data points and the green circles indicate the infected cells transfected with DG-d1 and the yellow circles indicate
uninfected cells transfected with DG-d1.
genomes. We were not able to develop a similar assay for DG-
d2. The assay was used to analyse the samples from three of
the experiments shown in Figure 2. Importantly, the transfection
efficiency for DG-d1 was similar to the infection efficacy. The
transfection reactions had placed similar numbers of defective
genomes into the cells as EBOV genomes had managed to infect
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(Figure 3). We found that the numbers of defective genomes in
the released supernatant were several orders of magnitude lower
than that of the released EBOV genomes (Figure 3). Moreover,
the numbers of defective genomes in the supernatant were not
different when comparing the cells that were transfected by
defective genome only and cells that were co-infected by both
EBOV and transfected defective genomes.
DISCUSSION
Two deletion defective genomes (Calain et al., 1999) were
synthetically reproduced. An experimental, in vitro, co-infection
system was developed for the analysis of the effect of defective
genomes on the growth of EBOV-Ecran. The defective genomes
were transfected after infection had occurred and residual virus
had been washed away. This was to reduce the likelihood of
artifacts in the virus replication cycle occurring because of
the lipofectamine used to transfect the cells with the defective
genome. Cumulative control data suggest that our experimental
system is robust. Some variation is observed in the quantified
viral uptake; however, this does not persist throughout the
experiment. Therefore, this variation is likely to be due to slight
differences in when samples were taken, rather than actual
differences in initial conditions. We found that the two deletion
defective genomes repeatedly reduced viral replication by ∼2-
fold compared to controls. This effect was most evident when
viral release was measured by qRT-PCR and the number of
genomes released; however, we observed some evidence that this
was the case also with infectious units (measured by TCID50).
The disparity in levels of confidence between these two measures
can be explained by the difference in precision of the two
assays. The TCID50 assay measurements are ordinal to the
level of number replicate wells and the number of dilutions
and the qRT-PCR is not and Ct/Cq values can be calculate to
many decimal points. We acknowledge however the possibility
exists that only released RNA is affected by the addition of
defective genomes. Additional work should be performed to
determine the function of these molecules in a dose dependent
manner, in line with Koch’s postulates. Indeed it is possible
that more favorable ratios of MOIs may exist. Here we used
one MOI of 5, which is quite high deliberately to maximize
the potential for cells to be co-infected by virus and defective
genome. Another way that the effect might be maximized would
be to change the time of defective genome intervention in
relation to viral infection. In single experiments (not shown
here) we looked at transfection of defective genome RNA prior
infection and close to the end of the anticipated eclipse stage
but saw no effect. The work we present here has infection prior
to transfection in case the transfections might be deleterious
to infection.
When Calain et al. co-infected naïve cells with the diversity
of DIPs and wild type virus and low passage virus, they
observed a near complete cessation of cytopathology (Calain
et al., 1999). The effect we observed was more modest.
We also found that the RNA control also had a lesser but
measurable negative effect on EBOV release (measured by qRT-
PCR). This may be driven by low level immune activation.
Vero cells are capable of responding to interferon, thus
demonstrating their immuno-competence; however, the cells
do not release interferon (Desmyter et al., 1968). There are
multiple points where single stranded RNA can be recognized
by the mammalian cell, reviewed in Jensen and Thomsen
(2012) and it is likely that the effect observed was driven
by one of these. It is unclear whether such an immune-
stimulating effect would be additive for the sequences encoding
the defective genomes.
We found that it is unlikely that defective genomes are
being released from infected cells as particles (or otherwise) in
our system. Despite this, it was still possible that the defective
genomes were being replicated within the cell. This presents
two possibilities: (1) defective particles were made but not
released or (2) they were not made. We were only able to
test the intracellular component of the assay once and saw
no replication of DG-d1 RNA (data not shown); however
both possibilities are possible when only a single experiment
is available for evidence. If we presume that the defective
genomes are not being replicated in the system, we might further
propose that the mechanism of action is that defective genomes
sequester protein resources. It is unclear why the defective
genomes were not replicated to a significant extent in the
presence of EBOV. However, understanding this phenomenon
could potentially inform about how viruses are able to evade
parasitisation by DIPs. Such adaptations would clearly convey
a selective advantage to the virus. We might postulate that
the RDRP might have some yet unknown ability to detect
truncated genomes, or that the EBOV genomes are chemically
modified in some way that the recombinately produced defective
genomes are not and the RDRP recognizes this. However this
is highly unlikely otherwise laboratory systems such as the
mini-replicon would not function and they do (Garcia-Dorival
et al., 2014). An alternative hypothesis is that the defective
genomes were not sufficiently co-located to interact with the
ribonucleoprotein (RNP). This is also not true because some
restricting effect on viral release was observed where defective
genomes and EBOV were placed inside cells together. Moreover,
we observed high numbers of both defective genome and wild-
type genome per cell. The only credible explanation these
authors have been able to postulate is that the RNP has some
way of prioritizing longer genomes. If the RNP is able to
bind anywhere to the RNA genome and then translocate to
the origin of synthesis; then, purely on the merit of its size
alone, our defective genomes will associate to an RNP once
for every 20 wild-type genomes. At this ratio, it is clear that
the defective genomes will quickly be out competed, especially
if RNPs stay associated to their genomes and are a rare
resource. This is likely to be true as the L protein is that
last to be transcribed during an EBOV infection of a cell
(Mühlberger, 2007).
Here we only present deletion defective genome data. We
did investigate the potential for copy-back variants; however we
did not observe an effect (data not shown, single experiment
for each). We attributed this to the palindromic nature of
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the copy-back genomes generating “hairpin” type structures
that then caused siRNA type effects (where the host cell
silences RNA using short templates of invasive RNA). These
“hairpin” type structures might be recognized by the Dicer
proteins and broken down into short duplexes. This would
obviously have to occur prior to the establishment of EBOV
VP35 suppression of Dicer co-factors (Fabozzi et al., 2011).
It was our hope that recombinately produced defective EBOV
genomes would have potential in reducing wild-type viral
replication by reproducing in competition for resources. While
an EBOV replication reducing effect was observed, this effect
was limited (approximately halving) and we observed no
significant release of the defective genomes. Further research
into why this phenomenon has occurred might reveal novel
aspects of how EBOV protects itself from parasitisation
by defective genomes and possibly even the function of
the RDRP.
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